Economics of Industry

Kettler, H.

September 2001

A number of potentially important structural developments are taking place in the pharmaceutical industry. On the one hand, we are witnessing a large number of mergers and acquisitions between companies across countries, suggesting a move towards a small number of large global players. On the other hand, a large number of new companies have entered in the industry over the past 15 years. Many are biotechnology companies that specialise in research and/or developing technologies for the discovery and pre-clinical stages of the research and development (R&D) process.

Pritchard, C. ed.

May 2001

It has long been known that a medicine may turn out to have an unexpected beneficial effect on an illness other than the one it was originally intended to treat. This is true for long established medicines, for example the cardiovascular benefits of aspirin, and for more recent products, of which Sildenafil (Viagra) is a dramatic example. Such instances are not rare and serendipidity has been a highly significant aspect of progress as illustrated by Julius Comroe’s (1977) fascinating dissection of the antecedents of some of the seminal advances in medicine.

Casper, S. and Kettler, H.

August 2000

The UK and Germany are the European leaders in biotechnology. They have many more companies and employees in biotechnology, and much greater sums invested in biotechnology research and development (R&D) than anywhere else in Europe. The two countries’ biotechnology sectors display important differences, however. Also, both remain well behind the US, the global leader in terms of number, size, maturity and profitability of biotechnology companies.

Danzon, P. and Chao, L.

June 2000

Most countries regulate manufacturer prices for pharmaceuticals, either directly (France, Italy) or indirectly through controls on reimbursement (Germany, Japan) or profits (the UK). It is widely believed that drug prices are lower in countries with strict price regulation than in countries with less restrictive regulation (the UK) or no regulation (the US). For example, the BEUC (1989b) concluded that prices in the UK and the US were, respectively, 20 and 54 percent above the EEC average, whereas those in France and Italy were, respectively, 30 and 28 percent below the EEC average.

Williams, P. and Clow, S.

October 1999

This Conference on Genomics, Healthcare and Public Policy, organised by the Office of Health Economics in collaboration with the School of Public Policy, University College London, and Pharmaceutical Partners for Better Healthcare, examined the status and likely consequences of healthcare applications of genetics. Advances in genetics will open up opportunities for universities and industry, they will induce changes in the practice of medicine, and lead to alterations in the structure and organization of health services in many countries.

Sussex, J. and Marchant, N. ed.

August 1999

This book has been built up from the papers delivered at the Office of Health Economics conference which took place at the Langham Hilton Hotel, London, on 5 December 1996.

Lane, S. and Phillips, J.

May 1999

A trade mark is, in its most basic sense, a badge of identity. Its most essential characteristic is its capacity to distinguish one undertaking's goods or services from those of another. This function is reflected in the legal definition of a trade mark in the law of the European Union (EU) and its Member States, which states:

'...a 'trade mark' means any sign capable of being represented graphically which is capable of distinguishing goods or services of one undertaking from those of other undertakings.'2

From an economist's point of view, trade marks

Mason, A.R., Towse, A. and Drummond, M.F.

March 1999

Disease management is a term with multiple and ambiguous meanings. For some, it is purely a form of managing care. For others, it is ‘strategic planning’ by the pharmaceutical industry to market its products in a different way. In between these two ends of the semantic spectrum are a wide variety of interpretations and usage. Forms of health care management exist that embody all the principles of disease management, but which are given a different label. In this report, we explore different notions of disease management and consider their relevance to the NHS.

Kettler, H.

February 1999

The objective of this paper is to analyse the existing estimates of NCE costs and look at the subsequent changes in cost components and at the impact of structural change in the R&D process. These discussions cannot substitute for new estimates that are based on more recent company data but, in the absence of such new estimates, they do provide some indication of the direction and magnitude of likely cost changes that have occurred in the 1980s and 1990s.

Kettler, H.

November 1998

Pharmaceutical companies report that in their dynamic, research and technology intensive industry, competitiveness is synonymous with innovativeness. That is, companies must invest in product research and development (R&D) to stay ahead. To afford this type of strategy, companies seek adequate reimbursement for their time, risk, and investments.


Subscribe to RSS - Economics of Industry